Replies to post #77757 on Savvy Trades and Investments

[RNsidersbuying]

yep and most of us watched ADIL yesterday spike all over the place on complete nonsense.

In addition to Gavins Felicity's main focus on NBIO's ongoing Phase 1 brain-cancer trial, NBIO has an ongoing corroboration with Syracuse Univ on a pre-clinical covid study in mice (updates any day now)...

“Our hope is that when we treat cells with Pritumumab, it will bind to CSV, and effectively block the SARS2 virus from entering the cell,” says Patteson. “An antibody that could block the entry of SARS2 into the cell could be a monumental step in the fight against COVID-19.”

Patteson will test the hypothesis on mouse embryo fibroblast cells and lung airway epithelial cells to determine if the antibody will block the uptake of SARS2. Using a cell in which vimentin has been knocked out, the results will provide an important control of Pritumumab effects.

https://www.nascentbiotech.com/nascent-biotech-announces-collaboration-with-syracuse-university-advancing-covid-19-research/

https://experts.syr.edu/en/clippings/us-nascent-biotech-syracuse-university-to-develop-covid-19-treatm

Unreal how this legitimate-potential-6 o'clock-newsmaker trades at .065 cents and approx. $5M cap.